Vor Biopharma Inc. (VOR) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 76.85M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 33.40M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -147.08M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $76.85M | (m) | $33.40M | $-147.08M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $312.43M | (m) | $25.85M | $-373.51M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $321.53M | (m) | $18.91M | $-371.64M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $327.69M | (m) | $13.52M | $-366.99M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $335.37M | (m) | $7.75M | $-367.40M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $95.69M | (m) | $8.70M | $-122.15M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $93.31M | (m) | $9.85M | $-121.19M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $88.86M | (m) | $10.03M | $-118.00M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $94.65M | (m) | $10.93M | $-124.80M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $96.72M | (m) | $12.38M | $-127.94M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $94.31M | (m) | $13.36M | $-126.04M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $90.48M | (m) | $15.35M | $-122.64M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $79.75M | (m) | $15.51M | $-111.42M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $71.19M | (m) | $13.02M | $-101.04M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $64.55M | (m) | $10.70M | $-93.42M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $60.18M | (m) | $8.02M | $-87.00M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $56.23M | (m) | $5.84M | $-81.50M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $53.87M | (m) | $5.17M | $-78.09M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $47.53M | (m) | $4.32M | $-69.02M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $31.62M | (m) | $1.34M | $-43.37M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |